30.78
0.15 (0.49%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Alto Neuroscience, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.17 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.48% |
| % Held by Institutions | 77.52% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alpha Wave Global, Lp | 30 Jun 2026 | 3,707,757 |
| Commodore Capital Lp | 30 Jun 2026 | 2,723,196 |
| Perceptive Advisors Llc | 30 Jun 2026 | 1,609,893 |
| Spruce Street Capital Lp | 30 Jun 2026 | 1,353,047 |
| Vivo Capital, Llc | 30 Jun 2026 | 1,208,858 |
| Armistice Capital, Llc | 30 Jun 2026 | 864,000 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 850,000 |
| Vestal Point Capital, Lp | 30 Jun 2026 | 785,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |